Latest From Genfit SA
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.
Cadila is exploring orphan indications for saroglitazar magnesium, in addition to the approaching Phase III NASH clinical trials for its lead NCE. Meanwhile, it counts on new product launches and biosimilars to take its FY21 growth story ahead.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.
With two new US investors on board, NST is financed to complete a Phase IIb trial of icosabutate in non-alcoholic steatohepatitis.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Hepatic (Liver)
- Immune Disorders
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- Genfit SA
- Senior Management
Jean-Francois Mouney, Chmn. & CEO
Nathalie Huitorel, EVP, CFO & Chief Administrative Officer
Dean Hum, PhD, COO
Carol L Addy, MD, CMO
- Contact Info
Phone: (33) 3 20 16 40 00
885 Ave. Eugene Avinee
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.